Form 4: Amicus Therapeutics Director Burke Whitman Reports Stock and Option Transactions

Director Burke Whitman reported the acquisition of restricted stock units and stock options in Amicus Therapeutics on June 6, 2024.

Summary

• On June 6, 2024, Burke Whitman, a director of Amicus Therapeutics, reported acquiring 11,847 restricted stock units (RSUs) and 42,467 stock options.
• The RSUs will vest in full on the one-year anniversary of the grant date and are payable in Amicus common stock.
• Each RSU is equivalent to one share of Amicus common stock.
• The stock options have an exercise price of $10.27 and will vest and become exercisable on the one-year anniversary of the grant date, expiring on June 6, 2034.
• Following these transactions, Whitman directly owns 98,184 shares of Amicus common stock and 42,467 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard Form 4 filing. The acquisition of shares and options by a director can be seen as a mildly positive signal, but it's not a strong indicator on its own.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition of shares and options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates